within Pharmacolibrary.Drugs.ATC.A;

model A03AA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.01583333333333333,
    adminDuration  = 600,
    adminMass      = 135 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.35,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0025,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A03AA04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Mebeverine is a musculotropic antispasmodic agent used to relieve symptoms of irritable bowel syndrome (IBS) such as abdominal pain and cramps, bowel disturbances, and intestinal discomfort. It acts primarily as a smooth muscle relaxant and is not associated with anticholinergic side effects. Mebeverine is still approved and used in several countries for IBS management.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported after oral administration of a single mebeverine 135 mg tablet in healthy adult volunteers.</p><h4>References</h4><ol><li><p>Stockis, A, et al., &amp; de Vos, D (2002). Identification of mebeverine acid as the main circulating metabolite of mebeverine in man. <i>Journal of pharmaceutical and biomedical analysis</i> 29(1-2) 335–340. DOI:<a href=\"https://doi.org/10.1016/s0731-7085(02)00023-7\">10.1016/s0731-7085(02)00023-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12062694/\">https://pubmed.ncbi.nlm.nih.gov/12062694</a></p></li><li><p>Dickinson, RG, et al., &amp; Hooper, WD (1991). Facile hydrolysis of mebeverine in vitro and in vivo: negligible circulating concentrations of the drug after oral administration. <i>Journal of pharmaceutical sciences</i> 80(10) 952–957. DOI:<a href=\"https://doi.org/10.1002/jps.2600801010\">10.1002/jps.2600801010</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1784004/\">https://pubmed.ncbi.nlm.nih.gov/1784004</a></p></li><li><p>Sommers, DK, et al., &amp; Eloff, JN (1997). Lack of bioavailability of mebeverine even after pretreatment with pyridostigmine. <i>European journal of clinical pharmacology</i> 53(3-4) 247–249. DOI:<a href=\"https://doi.org/10.1007/s002280050370\">10.1007/s002280050370</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9476039/\">https://pubmed.ncbi.nlm.nih.gov/9476039</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A03AA04;
